Cisplatin/Epinephrine

顺铂/肾上腺素

Report date: 2024/06/27 20:00:09

Base Information

Drug NameCisplatin/Epinephrine
Drug Alias NameEpinephrine+Cisplatin顺铂+肾上腺素Epinephrine/Cisplatin肾上腺素/顺铂Cisplatin+Epinephrine +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA cross linking agentsDNA synthesis inhibitorsAdrenergic receptors agonists
TargetsDNAAdrenergic receptors
Therapy Area/IndicationsHead and Neck NeoplasmsLiver Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesHong Kong
CombinationsYes Epinephrine BitartrateCisplatin
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMatrix Pharmaceutical
Active IndicationsN/A
Inactive IndicationsHead and Neck NeoplasmsLiver Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A